Summary of Key Points
The NewCo model represents an "upgraded version" of how Chinese innovative drugs enter the global market: these drugs are packaged into separate companies, which then collaborate with overseas investment institutions and professional teams for operation. This approach is more profitable than the traditional method of simply selling the drug development pipeline in exchange for an upfront payment, as it generates revenue from licensing fees, equity appreciation, and long-term benefits. The number of transactions involving NewCo models has surged rapidly within two years (from 7 in 2025 to 16, with a total value of $16.3 billion), benefiting both small overseas biotechs, investment firms, and Chinese pharmaceutical companies. However, a critical moment of validation has arrived: the first batch of core drug pipelines must produce results from global Phase III clinical trials. The quality of these data will directly determine whether the NewCo model can continue to be successful and whether Chinese innovative drugs truly possess global competitiveness.
I. The NewCo Model: Giving Drug Pipelines Their Own Chance to Succeed
In simple terms, the NewCo model creates an independent company for each drug pipeline. Previously, when Chinese pharmaceutical companies sought to enter overseas markets, they would sell their pipelines to foreign firms and receive an upfront payment, with additional payments based on milestones such as successful clinical trials or market approval—this was a one-time transaction. With the NewCo model, Chinese companies retain a portion of the shares in the newly established company while attracting overseas investment and hiring professional teams to manage it. This strategy allows them to earn not only initial licensing fees but also potential gains from the company's future financing, listing, or acquisition by larger pharmaceutical firms. It essentially transforms the business model from selling a product to co-investing in a startup, resulting in higher and more sustainable profits.
II. Why Has the NewCo Model Suddenly Become Popular?
The success of the NewCo model is due to the mutual needs of both Chinese pharmaceutical companies and overseas institutions:
- For Chinese companies: The cost of conducting clinical trials and commercializing drugs abroad (e.g., several times higher in the U.S.) is prohibitive, and they lack the necessary experience. The NewCo model enables overseas teams to handle these tasks while providing early financial returns and equity benefits.
- For overseas institutions: Following the recent capital downturn, many small biotechs in Europe and America are struggling due to a shortage of promising drug pipelines and funding. Chinese innovative drugs, with their attractive cost-effectiveness (lower licensing fees compared to local offerings), have become a valuable asset. For example, Vor Bio, a partner of Rongchang Biotech, saw its stock price soar from $2.6 per share to nearly $65 after acquiring Rongchang's drug candidate Taisetip, resulting in a market value of nearly $1.4 billion.
III. Who Has Benefited from the NewCo Model? A Win-Win Situation for All Involved
The NewCo model has created opportunities for various stakeholders:
- Small overseas biotechs: They have seen their valuations soar and avoided delisting by acquiring Chinese drug pipelines.
- Overseas investment institutions: They can profit from stock price increases (e.g., Hengrui's Kailera rose 60% on its first day of trading) or from the acquisition of their companies by larger pharmaceutical firms (e.g., CanSinoBio's Ouro was acquired by Gilead for $1.675 billion).
- Chinese pharmaceutical companies: They receive licensing fees and share in future profits, with significant gains from the listing of their NewCo companies.
- Professional management teams: Overseas teams managing NewCo companies can earn substantial returns if the businesses are successful.
IV. The Critical Moment of Proof: Clinical Trial Data
Financing and listing are just the beginning; the true test of the NewCo model lies in whether the drug pipelines can pass the most stringent global standards—global multi-center Phase III clinical trials. More than a dozen Chinese NewCo pipelines have entered overseas trials, with some of the fastest-progressing projects including Rongchang's Taisetip (Phase III for myasthenia gravis expected in the first half of 2027), Hengrui's Repopeptide (Phase III for obesity indications), and Innovent Biologics' bispecific antibody (Phase III for ocular diseases). The quality of these trial results will determine:
- Whether the drugs can be successfully marketed abroad.
- Whether the NewCo model is a viable strategy.
- Whether Chinese innovative drugs are recognized for their actual value in the global market.
V. The Big Test: Can Chinese Innovative Drugs Become Global Players?
If the Phase III trial data meet expectations, Chinese innovative drugs will transition from being seen as cost-effective options to having genuine global competitiveness. The NewCo model will then evolve from a temporary capital-driven strategy to a sustainable pathway for Chinese pharmaceutical companies to enter international markets. Conversely, if the data are unsatisfactory, the model's credibility will be questioned, and the trust in Chinese innovative drugs will decline. The next 2-3 years will be crucial for determining whether Chinese innovation can truly establish itself on the global stage.
In summary, while the NewCo model has accelerated the internationalization of Chinese innovative drugs, its long-term success depends on the outcomes of these clinical trials. It represents a necessary step for Chinese companies to move from being mere imitators to genuine global players in the pharmaceutical industry.